Pharma Exec Blog » Podcasts http://blog.pharmexec.com The Business of Pharmaceuticals Fri, 17 May 2013 20:46:32 +0000 en hourly 1 ©Advanstar Communications gkoroneos@advanstar.com (Advanstar Communications) gkoroneos@advanstar.com(Advanstar Communications) Pharmceuticals 1440 pharma, pharmaceuticals, life science, business, news, pharmexec, unplugged The Business of Pharmaceuticals Advanstar Communications Advanstar Communications gkoroneos@advanstar.com No no http://lifeinabungalo.com/art/pharmaunplugged_300x30.jpg Pharma Exec Blog http://blog.pharmexec.com 144 144 Supreme Court to Consider Sales Rep Overtime http://blog.pharmexec.com/2012/04/12/supreme-court-to-rule-on-overtime-for-reps/ http://blog.pharmexec.com/2012/04/12/supreme-court-to-rule-on-overtime-for-reps/#comments Thu, 12 Apr 2012 17:56:27 +0000 Reid Paul http://blog.pharmexec.com/?p=3824

]]> http://blog.pharmexec.com/2012/04/12/supreme-court-to-rule-on-overtime-for-reps/feed/ 0 Pharma Unplugged #2 Layoffs & Bonuses http://blog.pharmexec.com/2009/12/07/pharma-unplugged-2-layoffs-bonuses/ http://blog.pharmexec.com/2009/12/07/pharma-unplugged-2-layoffs-bonuses/#comments Mon, 07 Dec 2009 16:27:43 +0000 George Koroneos http://blog.pharmexec.com/?p=1230 Pharma Unplugged #2— Layoffs & Bonuses
Recorded: 12/3/2009
Air Date: 12/7/2009
Host: George Koroneos, Pharm Exec
Cohost: Reid Paul, Pharm Rep Magazine

Show Notes:
This week we discuss:

  • Pfizer’s medical education relationship with the Canadian Medical Association
  • Journalists take FDA to task for not being transparent enough
  • Layoffs and job cuts at Sanofi-Aventis
  • New report shows that DTC receives more funding than sales calls in certain drug categories
  • CEO compensation bump in life science

To subscribe add this feed to your favorite media player:

http://feeds.feedburner.com/pharmapodcast

Reblog this post [with Zemanta]
]]> http://blog.pharmexec.com/2009/12/07/pharma-unplugged-2-layoffs-bonuses/feed/ 0 39:18 Pharma Unplugged #2mdash; Layoffs #38; Bonuses Recorded: 12/3/2009 Air Date: 12/7/2009 Host: George Koroneos, Pharm Exec Cohost: Reid Paul, Pharm Rep Magazine Show Notes: This week we discuss: Pfizer's medical education relationship ... Pharma Unplugged #2mdash; Layoffs #38; Bonuses Recorded: 12/3/2009 Air Date: 12/7/2009 Host: George Koroneos, Pharm Exec Cohost: Reid Paul, Pharm Rep Magazine Show Notes: This week we discuss: Pfizer's medical education relationship with the Canadian Medical Association Journalists take FDA to task for not being transparent enough Layoffs and job cuts at Sanofi-Aventis New report shows that DTC receives more funding than sales calls in certain drug categories CEO compensation bump in life science To subscribe add this feed to your favorite media player: http://feeds.feedburner.com/pharmapodcast pharma,,pharmaceuticals,,life,science,,business,,news,,pharmexec,,unplugged Advanstar Communications no No Pharm Exec Podcast Series: Bill Trombetta Industry Audit (Part 3) http://blog.pharmexec.com/2009/02/04/pharm-exec-podcast-series-bill-trombetta-industry-audit-part-3/ http://blog.pharmexec.com/2009/02/04/pharm-exec-podcast-series-bill-trombetta-industry-audit-part-3/#comments Wed, 04 Feb 2009 17:17:19 +0000 George Koroneos http://blog.pharmexec.com/?p=605
Continuing Pharm Exec editor Patrick Clinton’s conversation with Bill Trombetta on the top four pharma companies and what makes them special.

Johnson & Johnson: A perennial member of the Top Four, J&J defies the conventional wisdom; it’s a big company that still manages to grow, a sprawling, diversified company that still has focus. And along with just three other companies on our list, it created shareholder value in 2007. Bill Trombetta explains how.

]]> http://blog.pharmexec.com/2009/02/04/pharm-exec-podcast-series-bill-trombetta-industry-audit-part-3/feed/ 0 12:36 Continuing Pharm Exec editor Patrick Clintonacirc;euro;trade;s conversation with Bill Trombetta on the top four pharma companies and what makes them special. Johnson #38; Johnson: A ... Continuing Pharm Exec editor Patrick Clintonacirc;euro;trade;s conversation with Bill Trombetta on the top four pharma companies and what makes them special. Johnson #38; Johnson: A perennial member of the Top Four, J#38;J defies the conventional wisdom; itacirc;euro;trade;s a big company that still manages to grow, a sprawling, diversified company that still has focus. And along with just three other companies on our list, it created shareholder value in 2007. Bill Trombetta explains how. Podcasts,,Strategy Advanstar Communications no No